Actavis has announced that after the United States District Court for the District of New Jersey denied AstraZeneca’s request for a permanent injunction and ruled that US Patent No. 7,524,834 is invalid, Actavis launched its generic version of AstraZeneca’s Pulmicort Respules budesonide inhalation suspension in 0.25 and 0.5 mg vials. The FDA approved Actavis’s ANDA for the budesonide suspension in August 2012.
AstraZeneca acquired Actavis’s branded respiratory products in the US and Canada earlier this month.
Read the Actavis press release.
